India to Guatemala: Amphotericin Export Trade Route

To import finished pharmaceutical formulations containing Amphotericin into Guatemala, the following approvals and registrations are mandated by the Department of Regulation and Control of Pharmaceutical and Related Products (DRCPFA) under the Ministry of Public Health and Social Assistance (MSPAS):

1. Sanitary Registration: All pharmaceutical products must obtain a sanitary registration from the DRCPFA before importation or commercialization. The registration process typically spans 4 to 6 months and requires renewal every five years.

3. Dossier Format: While the Common Technical Document (CTD) or electronic CTD (eCTD) formats are widely recognized, Guatemala's specific requirements may vary. It is advisable to consult the DRCPFA for precise dossier format guidelines.

4. GMP Inspection Requirements: The DRCPFA mandates that manufacturing facilities comply with Good Manufacturing Practices (GMP). Indian manufacturers must provide a valid GMP certificate issued by the competent authority in their country, duly legalized by Apostille for use in Guatemala. (latinalliance.co)

Indian exporters of Amphotericin formulations to Guatemala must adhere to stringent GMP standards to ensure product quality and safety:

1. GMP Certification: Manufacturing facilities must possess a valid GMP certificate issued by the relevant authority in India. This certificate should be legalized by Apostille to be recognized by Guatemalan authorities. (latinalliance.co)

3. Regulatory Actions: There have been no recent public records of regulatory actions by the DRCPFA against Indian pharmaceutical companies exporting to Guatemala. However, exporters are advised to maintain compliance with all regulatory requirements to avoid potential issues.

In the past 18 months, several regulatory changes have impacted the importation of pharmaceutical products into Guatemala:

1. Update to Controlled Substances Forms: In September 2025, the DRCPFA updated the commitment letter forms for establishments handling psychotropic drugs and narcotics. The new versions, F-SI-d-01 Version 6-2025 and F-SI-d-02 Version 5-2025, reflect revised formal commitments required from establishments managing these substances. (latinalliance.co)

2. Importation in Special Cases: As of April 2025, the DRCPFA outlined procedures for the importation of pharmaceutical products in special cases, such as for catastrophic, rare, or orphan diseases, and for human clinical research purposes. These procedures are detailed in Technical Standard Number 26, specifically in Article 3, Section II of the "Procedure for the Issuance of Import Permits." (latinalliance.co)

3. Pharmacovigilance Requirements: Guatemala's National Pharmacovigilance Program mandates that companies authorized to market pharmaceutical products must have an appropriate pharmacovigilance system. This includes designating a qualified professional responsible for monitoring the safety and efficacy of medicines. (latinalliance.co)

These developments underscore the importance of staying informed about regulatory changes to ensure compliance and facilitate the smooth importation of pharmaceutical products into Guatemala.

As of 2024, Guatemala's total pharmaceutical imports amounted to $1.12 billion. While specific data on Amphotericin formulations is limited, the country's reliance on imports for specialized medications suggests a significant portion of these imports includes antifungal treatments like Amphotericin. The demand for such medications is driven by the prevalence of fungal infections, particularly among immunocompromised individuals, and the country's ongoing efforts to improve healthcare access and outcomes. Domestic production of Amphotericin formulations is minimal, making imports essential to meet national demand.

Guatemala's import duty for finished pharmaceutical formulations under HS code 30049029 is set at 5%. In addition to this duty, imports are subject to a Value Added Tax (VAT) of 12%. There are no existing free trade agreements between India and Guatemala that provide preferential tariff rates for pharmaceutical products. Furthermore, there are no anti-dumping duties imposed on these imports.

India is a notable supplier of Amphotericin formulations to Guatemala, accounting for approximately 1.3% of India's total exports of these products, valued at $1.2 million across seven shipments. The primary Indian exporters include Bharat Serums and Vaccines Limited ($0.7 million), Remus Pharmaceuticals Pvt Ltd ($0.4 million), S R S Pharmaceuticals Private Limited ($0.1 million), and Caplin Point Laboratories Limited. The main Guatemalan importers are Solmedica S.A. ($0.7 million), Arael de Centroamerica S.A. ($0.4 million), Aviv Farmaceutica Sacalzada Atanasio Tzul ($0.1 million), and Nuevos Eticos Neoethicals S.A. While specific data on other supplying countries and pricing comparisons are not readily available, India's established pharmaceutical industry and competitive pricing position it as a key player in Guatemala's Amphotericin market.

India is a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic drugs. As of 2024, the country has 752 FDA-approved manufacturing facilities and 2,050 WHO-GMP certified plants, underscoring its robust manufacturing capabilities.

The Indian pharmaceutical industry is valued at around $50 billion as of 2024, with a significant portion dedicated to the production of finished dosage forms, including Amphotericin formulations. The country's cost-effective production methods, supported by a skilled workforce and advanced manufacturing infrastructure, enable the production of high-quality formulations at competitive prices. Additionally, India's extensive network of WHO-GMP and FDA-approved facilities ensures compliance with international quality standards, making it a preferred source for Amphotericin formulations globally.

India's Amphotericin formulations are recognized for their cost-effectiveness and high quality. The country's pharmaceutical exports have been growing at a rate of 9%, nearly twice the global average, indicating strong global acceptance.

In comparison, China's generic pharmaceutical industry is expanding but often faces challenges related to quality perception and regulatory compliance. The European Union (EU) primarily produces branded generics, which are typically priced higher than Indian formulations. For buyers in Guatemala, sourcing from India offers a balance of affordability and quality, with Indian formulations meeting international regulatory standards and having a reliable supply track record.

India's pharmaceutical industry has demonstrated a strong track record in supply reliability. The country has surpassed the US in the number of FDA-registered generic manufacturing sites, with 752 FDA-approved facilities as of 2024. This extensive manufacturing capacity ensures consistent production and supply of Amphotericin formulations.

Indian manufacturers have also invested in advanced packaging and cold chain logistics to maintain product integrity during transit. There have been no significant supply disruptions reported in recent years, indicating a stable supply chain. Furthermore, Indian pharmaceutical companies have a strong regulatory compliance record, adhering to international standards set by agencies such as the FDA and WHO.

For Guatemalan buyers sourcing Amphotericin formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Indian exporters typically require MOQs to optimize production and logistics. It's advisable to negotiate MOQs that align with your demand forecasts to balance cost and inventory management.

• Payment Terms: Common payment terms in India-Guatemala pharmaceutical trade include Letters of Credit (LC) and advance payments. Establish clear payment agreements to maintain trust and financial stability.

• Supplier Qualification Process: Conduct thorough due diligence on potential suppliers, including audits of manufacturing facilities, verification of regulatory certifications (e.g., FDA, WHO-GMP), and assessment of financial stability.

• Regulatory Compliance: Ensure that the selected Indian manufacturers comply with both Indian and Guatemalan regulatory requirements to facilitate smooth importation and distribution.

By implementing these strategies, Guatemalan buyers can establish a reliable and cost-effective supply chain for Amphotericin formulations sourced from India.

By adhering to this structured approach, Guatemalan companies can effectively qualify Indian suppliers of Amphotericin formulations, ensuring compliance with regulatory standards and safeguarding public health.